Join Jason Kelly, CEO of Ginkgo Bioworks, and Matthew Harrison, a biotech analyst at Morgan Stanley, as they delve into Moderna's innovative journey in biotech. They discuss how Moderna's mRNA technology acts like the software of life, revolutionizing vaccine development. The conversation touches on the evolution of biotechnology, strategic shifts from traditional methods to advanced automation, and the financial dynamics shaping the pharmaceutical landscape. Discover how Moderna's unique business model positions it for future breakthroughs in drug development.
